Patients who have mutations in genes including TP53, BRCA1, BRCA2, CDH1, PALB2, ATM, or have an inherited syndrome such as Peutz-Jeghers syndrome, PTEN, Hamartoma tumor syndromes, Neurofibromatosis type 1 are at a higher risk of developing malignancy, so this cohort of patients may need an earlier qualification for biopsy or removal of the lesion (34). Here, BRCA2 is linked to neurofibromatosis type 1.